Prolia (denosumab) is approved in Canada for the treatment of osteoporosis in men and postmenopausal females. it is given as an injection every 6 months and significantly reduces fracture risk.
Until now, the government coverage through plans such as Trillium or for seniors aged 65 and over, only provided Prolia for women based on specific criteria. As of January 31st, this coverage has been extended to men who are at high risk for a fracture and who have either had adverse effects or lack of efficacy to swallowed osteoporosis medications such as Fosamax or Actonel.
The criteria for coverage for women has also been changed, with the age restriction of being over 75 being removed.
If you have osteoporosis, be sure to discuss this new coverage with your physician to see how it might effect you.
Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.
Pulmonary arterial hypertension occurs when there is increased pressure in the small blood vessels that…
Polymyalgia rheumatica (PMR) is an inflammatory condition that causes widespread joint and muscle pain along…
Respiratory Syncytial Virus (RSV) is a common virus that can cause serious lung infections, particularly in…
Health Canada has recently approved Rinvoq (upadacitinib) for adults living with Giant Cell Arteritis (GCA). Rinvoq…
Every year on October 12, World Arthritis Day raises awareness about the millions of people…
Tremfya (guselkumab) has been available for several years to treat plaque psoriasis and psoriatic arthritis.…